The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BVNR.Y | +17.79% | +32.5% | +5.78% | +131% |
| S&P | +19.89% | +109.18% | +15.89% | +272% |
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.
Vaccine companies saw stock prices spike during the COVID pandemic. The same could happen amid a new outbreak.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $251.37M | 22.1% |
| Gross Profit | $139.19M | 34.2% |
| Gross Margin | 55.37% | 5.0% |
| Market Cap | $2.06B | 6.5% |
| Market Cap / Employee | $1.23M | -11.8% |
| Employees | 1.7K | 20.7% |
| Net Income | $55.12M | 46.3% |
| EBITDA | $82.66M | 37.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $192.05M | 63.7% |
| Accounts Receivable | $142.27M | -6.6% |
| Inventory | 416.3 | 45.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.78M | 24.3% |
| Short Term Debt | $6.63M | 10.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.75% | 5.0% |
| Return On Invested Capital | 3.28% | 4.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $175.00M | 108.8% |
| Operating Free Cash Flow | $183.27M | 101.3% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.71 | 16.53 | 8.98 | 10.07 | -16.89% |
| Price to Book | 1.78 | 1.29 | 1.07 | 1.23 | -6.40% |
| Price to Sales | 2.20 | 3.08 | 1.88 | 2.19 | 20.71% |
| Price to Tangible Book Value | 4.74 | 3.22 | 2.41 | 2.67 | -24.65% |
| Price to Free Cash Flow TTM | 6.88 | 11.75 | 10.97 | 8.45 | 15.45% |
| Enterprise Value to EBITDA | 43.18 | 18.74 | 25.55 | 22.13 | -7.26% |
| Free Cash Flow Yield | 14.5% | 8.5% | 9.1% | 11.8% | -13.38% |
| Return on Equity | 11.0% | 9.1% | 12.0% | 12.2% | 75.35% |
| Total Debt | $17.11M | $17.81M | $16.93M | $21.41M | 19.53% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
